Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan
Sponsor:Apellis Pharmaceuticals Inc.

Contact Research Centre

Ischaemic stroke

Not yet recruiting

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug

Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

Registered drug

France

Participants:18–64 years · 65+ years
Substances:RADAMTS13
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Endometrial cancer+6

Not yet recruiting

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

InvestigationalNo placebo

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lirafugratinib hydrochloride
Sponsor:Elevar Therapeutics Inc.

Contact Research Centre

Homocystinuria

Not yet recruiting

Safety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)

InvestigationalNo placebo

Safety and Tolerability Study of Subcutaneous Pegtibatinase in Adults and Children with Classical Homocystinuria (Phase 1/2)

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegtibatinase
Sponsor:Travere Therapeutics Inc.

Contact Research Centre

Allogenic stem cell transplantation+1

Not yet recruiting

Immunogenicity and safety of RSV A/B prefusion F protein vaccine versus RSV F glycoprotein recombinant adjuvanted vaccine in lung and stem cell transplant recipients

Registered drugNo placebo

Immunogenicity and safety of RSV A/B prefusion F protein vaccine versus RSV F glycoprotein recombinant adjuvanted vaccine in lung and stem cell transplant recipients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
Sponsor:Hospices Civils De Lyon

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Unicancer

Contact Research Centre

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Cystic fibrosis

Not yet recruiting

Effect of Stopping Long‑Term Azithromycin in Stable Non‑Cystic Fibrosis Bronchiectasis Patients: A Randomized Controlled Trial

Registered drugNo placebo

Effect of Stopping Long‑Term Azithromycin in Stable Non‑Cystic Fibrosis Bronchiectasis Patients: A Randomized Controlled Trial

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azithromycin
Sponsor:Centre Hospitalier Intercommunal Creteil

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

NBTXR3 with radiotherapy
EGFR-ADC therapy combinations
HPV-positive oropharyngeal cancer

02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

Anti-CEACAM5 ADC therapy
Sotorasib combinations
Novel gastrointestinal cancer treatments

03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

Elranatamab-lenalidomide therapy
Belantamab mafodotin combinations
T-cell lymphoma treatments

04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

Novel antibody-drug conjugates
Microbiome-based approaches
Targeted therapy combinations

05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

PARG inhibitor studies
Targeted molecular therapies
Immunotherapy combinations

Back to France All countries